The development of biomarkers based on quantitative imaging provides powerful non-invasive and cost-effective diagnostic tools for stratified medicine. Brainomix Limited, a start-up company from the University of Oxford, aims to become leaders in imaging biomarkers for neurological and cerebrovascular disorders.
Having the right people in place is essential to our success. Find out more about the people behind Brainomix.
We aim to become leaders in imaging biomarkers for neurological disorders.
The clinical need
e-ASPECTS software automatically assesses and quantifies early ischaemic brain damage on CT scans....
- Speed up the decision making process improving patient outcomes
- Reduce hospitalisation costs by limiting length of stay
- Increase the uptake of stroke treatments.
Try e-ASPECTS instant online demo system
Brainomix at ANIM 2016
Jan. 26, 2016
Brainomix will be attending the 33rd Annual Meeting of the German Stroke Society – ANIM 2016 in Berlin Germany, Jan 28-30. Over 1,500 visitors from Germany and abroad gather each year to discuss the latest...
Brainomix announces a new release for its e-ASPECTS software (v4.8)
Dec. 7, 2015
Oxford - December 7, 2015 - Brainomix announces a new release for its e-ASPECTS software (v4.8). The new version improves performance and offers several new features, including:
UK Stroke Forum 2015
Dec. 1, 2015
Oxford, Tuesday 1 December 2015 - Brainomix is attending this year’s UK Stroke Forum in Liverpool. The UK Stroke Forum is the largest multidisciplinary conference for stroke care professionals in the UK. The...
Discover press releases, news articles and social media updates from Brainomix.
See us at:
Jan. 28, 2016
@OxfordAHSN June 30, 2015
@Brainomix benefits for patients, for clinicians and hospital spend! #OxTechShowcase - must be a winner for us all
Delivering efficient and effective healthcare has never been more important, and innovation is central to making that happen.